Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Subscribe To Our Newsletter & Stay Updated
